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IMPORTANCE Dual antiplatelet therapy after percutaneous coronary intervention (PCI)
reduces ischemia but increases bleeding.
OBJECTIVE To develop a clinical decision tool to identify patients expected to derive benefit
vs harm from continuing thienopyridine beyond 1 year after PCI.
DESIGN, SETTING, AND PARTICIPANTS Among 11 648 randomized DAPT Study patients from 11
countries (August 2009-May 2014), a prediction rule was derived stratifying patients into
groups to distinguish ischemic and bleeding risk 12 to 30months after PCI. Validation was
internal via bootstrap resampling and external among 8136 patients from 36 countries
randomized in the PROTECT trial (June 2007-July 2014).
EXPOSURES Twelve months of open-label thienopyridine plus aspirin, then randomized to 18
months of continued thienopyridine plus aspirin vs placebo plus aspirin.
MAIN OUTCOMES ANDMEASURES Ischemia (myocardial infarction or stent thrombosis) and
bleeding (moderate or severe) 12 to 30months after PCI.
RESULTS AmongDAPT Study patients (derivation cohort; mean age, 61.3 years; women,
25.1%), ischemia occurred in 348 patients (3.0%) and bleeding in 215 (1.8%). Derivation cohort
models predicting ischemia and bleeding had c statistics of 0.70 and0.68, respectively. The
prediction rule assigned 1 point each formyocardial infarction at presentation, priormyocardial
infarction or PCI, diabetes, stent diameter less than 3mm, smoking, and paclitaxel-eluting stent;
2 points each for history of congestive heart failure/low ejection fraction and vein graft
intervention; −1 point for age 65 to younger than 75 years; and −2 points for age 75 years or
older. Among the high score group (score2, n = 5917), continued thienopyridine vs placebo
was associatedwith reduced ischemic events (2.7% vs 5.7%; risk difference [RD], −3.0% [95%
CI, −4.1% to −2.0%], P < .001) comparedwith the low score group (score <2, n = 5731; 1.7% vs
2.3%; RD, −0.7% [95%CI, −1.4% to0.09%], P = .07; interaction P < .001). Conversely,
continued thienopyridinewas associatedwith smaller increases in bleeding among the high
score group (1.8% vs 1.4%; RD, 0.4% [95%CI, −0.3% to 1.0%], P = .26) comparedwith the low
score group (3.0%vs 1.4%; RD, 1.5% [95%CI, 0.8% to 2.3%], P < .001; interaction P = .02).
Among PROTECT patients (validation cohort; mean age, 62 years; women, 23.7%), ischemia
occurred in 79 patients (1.0%) and bleeding in 37 (0.5%), with a c statistic of 0.64 for ischemia
and0.64 for bleeding. In this cohort, the high-score patients (n = 2848) had increased ischemic
events comparedwith the low-score patients and no significant difference in bleeding.
CONCLUSION AND RELEVANCE Among patients not sustainingmajor bleeding or ischemic
events 1 year after PCI, a prediction rule assessing late ischemic and bleeding risks to inform
dual antiplatelet therapy duration showedmodest accuracy in derivation and validation
cohorts. This rule requires further prospective evaluation to assess potential effects on
patient care, as well as validation in other cohorts.
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T he optimal duration of dual antiplatelet therapy withaspirin and thienopyridine after percutaneous coro-nary intervention (PCI) with stents is the subject of
debate. Among patients who complete 1 year of dual anti-
platelet therapy after PCI without an ischemic or bleeding
event, continuing therapy decreases stent thrombosis and
myocardial infarction but increases bleeding.1,2 Continuing
dual antiplatelet therapy thus involves a careful assessment
of the trade-offs between reduced ischemia and increased
bleeding for individual patients.
However, assessing the balance between ischemia and
bleeding risks can be challenging for clinicians and patients.
Factors related to recurrent ischemic events and bleeding in
patients undergoing PCI overlap substantially, making it diffi-
cult to determine optimal
treatment.3Althoughsub-
group analyses have been
helpful in determining
groups with larger abso-
lutebenefits fromcontinu-
ing therapy (eg, patients
presenting with myocar-
dial infarction),4,5 there re-
mainpatientswithin these
broad categories who may also experience serious bleeding
events. Most data estimating ischemia and bleeding risk fol-
lowing PCI have focused on early risks, including periproce-
duralevents.6,7 It remainsunclearwhichpatientsareathighrisk
for late ischemiceventsandmaythusbenefitmost fromlonger-
termdual antiplatelet therapy vs thosewho are at high risk for
late bleeding events andmay thus be harmed.
The goal of this study was to identify factors predicting
whether the expectedbenefit of reduced ischemiawouldout-
weigh the expected increase in bleeding associatedwith con-
tinued dual antiplatelet therapy beyond 1 year for individual
patients,usingdata fromtheDualAntiplateletTherapy (DAPT)
Study. These factors were used to develop a decision tool to
helpselect thedurationof therapy for individualpatientsbeing
evaluated 1 year after stenting.
Methods
This secondary analysis of the DAPT Study was approved by
the institutional review board of Partners HealthCare. The
Patient-RelatedOutcomesWith Endeavor vs Cypher Stenting
(PROTECT) protocolwas approvedby ethical boards in accor-
dancewith local regulations. All patients in both studies pro-
videdwritten informed consent. TheDAPT Study, conducted
from August 2009 to May 2014 in 11 countries, enrolled pa-
tients after PCI with either drug-eluting stents (DES) or bare
metal stents (BMS) and treated themwith open-label thieno-
pyridine plus aspirin for 12months; at 12months, eligible pa-
tientswhowere free frommajor bleeding and ischemic events
andadherent to therapy remained takingaspirinandwere ran-
domized to continued thienopyridine vs placebo for 18
months.8 The full enrollment and randomization criteria are
listed in the eAppendix in the Supplement. Patients receiving
long-termanticoagulation therapy, thosewith planned surgi-
cal procedures necessitating discontinuation of antiplatelet
therapy for more than 14 days, and those with a life expec-
tancy of less than 3 years were excluded from enrollment. At
12 months, only those patients who were adherent with thi-
enopyridine therapy and free from myocardial infarction,
stroke, repeat coronary revascularization, stent thrombosis,
and moderate or severe bleeding by the GUSTO (Global Utili-
zation of Streptokinase and Tissue PlasminogenActivator for
OccludedArteries) criteria9during the first 12monthsafter en-
rollment were randomized.
As permitted by regulatory authorities, race and ethnic-
ity data were collected via patient self-report. Race catego-
ries were prespecified as American Indian or Alaska Native,
Asian, blackorAfricanAmerican,NativeHawaiianorotherPa-
cific Islander,white, andother. Ethnicitywas collected asHis-
panic or Latino and not Hispanic or Latino. This information
was collected to assess potential heterogeneous treatment ef-
fects among different subgroups.
The primary follow-up period of the study was 12 to 30
months after the indexprocedure (or 18months after random-
ization). Details of the study design and results have been de-
scribed previously.1,2,8 As the results of the study were con-
sistent acrossDES- andBMS-treated cohorts,2 all randomized
patients were included in this analysis.
Study Goals
The goal of this study was to distinguish patients within the
DAPT Studywhoderived the greatest benefit from thosewho
experienced the most harm from continuation of dual anti-
platelet therapy more than 1 year after PCI, considering indi-
vidual patient characteristics and their independent associa-
tionswith ischemic andbleeding events. This study sought to
stratify outcomes basedon a singlemultivariable risk score.10
This entailed (1) identifying factors associated with ischemic
and bleeding risks, (2) choosing those that selectively pre-
dicted either ischemic or bleeding risk to generate a simpli-
fied risk score, and (3) assessing the randomized treatment re-
sults observed in the trial, stratified by the new risk score. An
ideal scorewould identify patientswith simultaneoushigh is-
chemic risk (and corresponding high benefit with continued
thienopyridine) and lowbleeding risk (and corresponding low
risk of harmwith continued therapy), and vice versa. In addi-
tion, the ability of the score to stratify ischemic and bleeding
risk within an external sample was assessed.
Ischemic and Bleeding End Points
The primary ischemic end point was a composite of myocar-
dial infarction or definite or probable stent thrombosis (as de-
fined by the Academic Research Consortium),11 and the pri-
mary bleeding end pointwasmoderate or severe bleeding (as
defined by the GUSTO criteria).9
Predictors
A total of 37 candidate variables potentially associated with
ischemic or bleeding events based on a comprehensive litera-
ture review and clinical plausibility were identified. Vari-
ables includedsociodemographicvariables, cardiovascularhis-
BMS bare metal stent
CHF congestive heart failure
DES drug-eluting stent
EES everolimus-eluting stent
PCI percutaneous coronary
intervention
SES sirolimus-eluting stent
ZES zotarolimus-eluting stent
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tory, noncardiovascular medical comorbidities, anatomical
and procedural factors, and concomitant medical therapy.
(Candidate Variables for Model Building in the eAppendix in
the Supplement).
Statistical Analysis
Development of Ischemic and Bleeding EventModels
Clinical and procedural characteristics were compared be-
tweenpatientsexperiencingevents from12through30months
and those without events, using Fisher exact or t tests as ap-
propriate. Cox regressionwasused todevelop2 separatemod-
els within the DAPT randomized study population (deriva-
tioncohort), the first topredict ischemiceventsand thesecond
topredict bleedingevents after randomization.Datawere cen-
sored at the time of amyocardial infarction or stent thrombo-
sis for the ischemiamodel; amoderate or severe bleed for the
bleeding model; or at the time of death, last known contact,
or 30months,whicheverwasearliest.Candidatevariables that
differed inbivariable comparisonsat a significance level of less
than .30were incorporated. Stepwise selectionwas then per-
formed, using the .05 significance level. To identify possible
heterogeneous treatment effects, simpleCox regressionmod-
els were developed for each outcome including treatment
group, variable of interest, and their interaction term. Inter-
actions terms significant at a P value less than .15 were en-
tered into the stepwise selection process with other candi-
date variables.
Proportionalitywas evaluated for all variables in themod-
els. Model discrimination was assessed using the c statistic.
Calibrationwas assessed through the examination of calibra-
tion plots and using the corrected Nam and D’Agostino good-
ness-of-fit test.12,13 The primary models were internally vali-
datedusingbootstrap resampling for200 iterations.14Foreach
resampling, the stepwise selectionprocesswas rerun, and the
discriminationof thebootstrapmodelwasassessed in theboot-
strap sample and the full data set. The mean difference be-
tween these bootstrap model values was defined as the “op-
timism,” and was subtracted from the final reported
discrimination of the models.15
Development of a Simplified Clinical Prediction Score
For each patient, the predicted risk (cumulative incidence) of
an ischemic event from 12 through 30monthswas estimated,
assuming treatment with continued thienopyridine plus as-
pirin beyond 12 months and separately assuming treatment
withaspirin alonebeyond 12months; similarly, bleedingevent
risks were predicted under these 2 assumptions. The differ-
ence between these 2 predicted values represented the pre-
dicted absolute risk reduction in combinedmyocardial infarc-
tion or stent thrombosis anticipated with continued
thienopyridine fromthe ischemicmodel, and thepredictedab-
solute risk increase in moderate or severe bleeding antici-
patedwithcontinued thienopyridine fromthebleedingmodel.
The absolute difference between the predicted ischemic re-
duction and bleeding increase was defined as the “benefit-
risk difference,” and estimated for each patient.
A linear regressionmodel was created, using benefit-risk
difference as the outcome and all predictors that were se-
lected in the ischemia andbleedingmodels.Variables that sta-
tistically accounted for more than 1% of the observed varia-
tion in estimated benefit-risk difference were included in a
simplified clinical prediction score. To facilitate ease of use,
continuousvariables (suchasageandstentdiameter)werecat-
egorized based on reference to prior studies or atmedian val-
ues and confirmation that the gradient of effect was main-
tained when transformed, and all variables were assigned an
integer score of 1 or 2 (or −1 to −2) based on β coefficients (De-
velopmentofaPredictiveScore in theeAppendix in theSupple-
ment). The range of potential scores was between −2 and 10.
Evaluation of Randomized Treatment Effect Stratified
by Clinical Prediction Score
The derivation cohort was divided into approximate quar-
tiles basedon the score, andKaplan-Meier event rates from12
through 30 months were compared within each score quar-
tile by randomized treatment group.Additionally, event rates
were examined among patients receiving only everolimus-
eluting stents (EES). Based on these results, clinically rel-
evant score groupings were created, defining patients more
likely to benefit from thienopyridine continuation (high score
group) vs those more likely to be harmed (low score group).
The absolute risk differences in ischemic and bleeding event
rates associated with continued thienopyridine vs placebo
across high vs low score groups were compared using a Z test
for interaction.
External Validation
The risk models and the clinical prediction score were exter-
nallyvalidatedwithin thePROTECTtrial, conducted fromJune
2007 through July 2014 in 36 countries, inwhichpatients un-
dergoing PCI were randomized to receive sirolimus-eluting
(SES) vs zotarolimus-eluting stents (ZES) and were followed
up for 5 years.16 This trial was selected for validation due to
its large inclusive population of stent-treated patients, with
similar definitions andadjudicatedoutcomes as thoseused in
theDAPTStudy. Those patients not sustainingmyocardial in-
farction, stent thrombosis,oramoderate/severebleedingevent
within the first 12 months in the PROTECT trial served as the
validationcohort (n = 8136).Twoformsofvalidationwerecon-
ducted: (1) evaluationof theDAPTStudy–derived ischemicand
bleeding models and (2) evaluation of prediction score per-
formance in stratifying risks of ischemic andbleeding events.
First, for the validation of themodels, because PROTECT trial
patients were not randomized to different durations of dual
antiplatelet therapy, dual antiplatelet therapy duration was
likely confounded by treatment indication andwas therefore
not included in the validation. The anticipated statistical ef-
fect of omitting this variable in thevalidationwouldbe toyield
a conservative estimate of each model’s performance, given
that randomized treatment group is strongly associated with
bothbleeding and ischemic events.Modelswerevalidatedvia
the estimation of c statistics and goodness-of-fit tests by ap-
plying the functionderived in theDAPTStudy toPROTECTpa-
tients from 12 through 30 months after PCI, limited to pa-
tients not sustainingmyocardial infarction, stent thrombosis,
or amoderate/severebleedingeventwithin the first 12months.
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Because PROTECT had lower overall ischemic and bleeding
event rates than the DAPT Study, the calibration of the mod-
els was assessed after accounting for this difference in base-
line hazard,17 and then the goodness of fit of the recalibrated
model was assessed.
Second, theabilityof theclinicalpredictionscore tostratify
ischemic and bleeding riskwas evaluated by comparing over-
all rates ofmyocardial infarction, stent thrombosis, andmod-
erateorseverebleedingamongpatientswithahighvs lowscore
in the validation cohort.
A 2-tailed α of .05 was used to define the significance
threshold for all comparisons. All analyseswere performed at
the Harvard Clinical Research Institute, using SAS (SAS Insti-
tute), version 9.4.
Results
Study Population
A total of 11 648patients undergoing PCIwith coronary stents
were randomized in theDAPTStudyand included in thisanaly-
sis (derivation cohort) (Figure 1). Of these, patients receiving
EESwere40.3%;paclitaxel-eluting stents, 22.9%; ZES, 10.9%;
SES, 9.6%;BMS, 14.4%; receivingmore than 1 stent type, 1.8%.
From 12 through 30 months after their index procedure, 348
patients (3.0%) developed myocardial infarction or stent
thrombosis (myocardial infarctionwithout stent thrombosis,
251; stent thrombosis, 97) and 215 patients (1.8%) developed
moderate or severe bleeding (moderate, 142; severe, 72; 2 dif-
ferent events adjudicated as moderate and severe, 1). Thirty-
three patients had both an ischemic and bleeding event in
follow-up.Patientswhohadan ischemicevent in follow-uphad
higher rates of cardiovascular risk factors (including diabe-
tes, hypertension, peripheral arterial disease, renal insuffi-
ciency/failure, and smoking), had higher rates of cardiovas-
cular disease (including history of congestive heart failure
[CHF], low ejection fraction, priormyocardial infarction, and
prior PCI), and were more likely to have been randomized to
placebo compared with patients without an ischemic event
(Table 1). Patientswithableedingeventwereolder,hada lower
prevalence of smoking, had a higher prevalence of hyperten-
sion, prior CHF, renal insufficiency/failure, peripheral arte-
rial disease, atrial fibrillation, prior stroke/transient ischemic
attack, prior PCI, and history of cancer, and were more likely
to have been randomized to continued thienopyridine com-
pared with patients without a bleeding event.
Risk PredictionModels
In multivariable Cox regression, significant predictors of both
ischemic and bleeding events included randomized treat-
ment group, peripheral arterial disease, hypertension, and
renal insufficiency/failure. Variables that predicted only the
risk of ischemic events included history of PCI or myocardial
infarction prior to the index procedure, stent diameter less
than 3 mm, myocardial infarction at presentation, history of
CHF or left ventricular ejection fraction lower than 30%,
paclitaxel-eluting stent, vein graft stent, cigarette smoking
within the year prior to index procedure, and diabetes melli-
tus (Table 2). No tested interactions between covariates and
randomized treatment for ischemic events were retained in
Figure 1. Flow of Patients Through the Dual Antiplatelet Therapy Study
25 682 Stent-treated patients enrolled a
22 866 DES-treated patients
2816 BMS-treated patients
5862 Randomized to receive continued
thienopyridine at 12 months
5020 DES-treated patients
842 BMS-treated patients
5786 Randomized to receive placebo
at 12 months
4941 DES-treated patients
845 BMS-treated patients
14 034 Excluded
5844 Were not eligible for randomization
8190 Were eligible but not randomized
55 Had unknown reason
6127 Withdrew consent
1970 Had randomization visit out of
window or lost to follow-up
38 Had other reasons c
335 Died
675 Had myocardial infarction
202 Had stroke
135 Had stent thrombosis
1845 Had revascularization
665 Had moderate or severe 
GUSTO bleeding
18 Did not meet enrollment criteria
2971 Had events b
1343 Were nonadherent
1512 Had other exclusion criteria
11 648 Randomized and included
in the derivation cohort
BMS indicates bare metal stent;
DES, drug-eluting stent;
GUSTO, Global Utilization of
Streptokinase and Tissue
Plasminogen Activator for Occluded
Arteries. A total of 11 648 randomized
patients comprised the cohort used
to derive a clinical prediction score to
stratify individual risk of benefit and
harmwith continuation of dual
antiplatelet therapy beyond 1 year
after percutaneous coronary
intervention.
a Screening for eligibility data are not
available to report.
b Patients may have hadmore than
1 event.
c Other reasons include site
terminated participation,
randomization target met prior to
patient follow-up, or patient not
recognized as eligible by site.
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Table 1. Baseline Characteristics of PatientsWith vsWithout Ischemic or Bleeding Events From 12 to 30Months in the Derivation Cohort (N = 11 648)a
Measure
Myocardial Infarction or Stent Thrombosis Events, No. (%) Moderate or Severe Bleeding Events, No. (%)b
Event
(n = 348 Patients)
No Event
(n = 11 300 Patients) P Value
Event
(n = 215 Patients)
No Event
(n = 11 433 Patients) P Value
Demographics
Age, mean (SD), y 61.7 (10.8) 61.3 (10.3) .47 66.4 (10.3) 61.2 (10.3) <.001
Median (IQR) 62.0 (54.0-69.0) 62.0 (54.0-68.6) 67.8 (60.0-74.0) 61.0 (54.0-68.0)
Women 92 (26.4) 2833 (25.1) .57 63 (29.3) 2862 (25.0) .15
Race/ethnicity
Hispanic or Latino ethnic group 17 (4.9) 389 (3.5) .18 8 (3.8) 398 (3.6) .85
Nonwhite racec 35 (10.3) 950 (8.6) .28 17 (8.0) 968 (8.6) .90
BMI, mean (SD) 30.1 (5.6) 30.4 (5.7) .28 29.5 (5.1) 30.4 (5.8) .01
Medical History
Diabetes mellitus 138 (39.9) 3253 (28.9) <.001 67 (31.3) 3324 (29.2) .50
Hypertension 282 (81.0) 8240 (73.1) <.001 181 (84.2) 8341 (73.2) <.001
Cigarette smoker 113 (33.0) 3029 (27.2) .02 39 (18.2) 3103 (27.6) .002
Stroke or TIA 20 (5.8) 381 (3.4) .02 16 (7.6) 385 (3.4) .003
Congestive heart failure 36 (10.4) 488 (4.3) <.001 17 (8.0) 507 (4.5) .02
LVEF <30% 15 (4.6) 192 (1.9) .002 6 (3.1) 201 (1.9) .28
Renal insufficiency/failure 27 (7.9) 441 (3.9) .001 20 (9.4) 448 (3.9) <.001
Peripheral arterial disease 37 (10.9) 612 (5.5) <.001 30 (14.3) 619 (5.5) <.001
Prior PCI 147 (42.4) 3221 (28.6) <.001 81 (37.7) 3287 (28.9) .01
Prior CABG 61 (17.5) 1188 (10.5) <.001 31 (14.4) 1218 (10.7) .09
Atrial fibrillation 13 (3.8) 327 (2.9) .33 12 (5.6) 328 (2.9) .04
Prior myocardial infarction 112 (32.7) 2344 (21.1) <.001 47 (22.2) 2409 (21.4) .80
History of cancer 36 (10.5) 1034 (9.2) .39 34 (16.0) 1036 (9.1) .002
Cancer reported prior to randomization
(0-12 mo)
2 (0.6) 48 (0.4) .66 3 (1.4) 47 (0.4) .07
Indication for Index Procedure
STEMI 50 (14.4) 1630 (14.4) >.99 22 (10.2) 1658 (14.5) .08
NSTEMI 77 (22.1) 1819 (16.1) .004 26 (12.1) 1870 (16.4) .11
Stable angina 110 (31.6) 4039 (35.7) .13 74 (34.4) 4075 (35.6) .77
Unstable angina 57 (16.4) 1764 (15.6) .71 37 (17.2) 1784 (15.6) .51
Other 54 (15.5) 2048 (18.1) .23 56 (26.1) 2046 (17.9) .003
Lesion and Procedure Characteristics
In-stent restenosis 30 (8.6) 513 (4.5) .001 13 (6.1) 530 (4.6) .33
No. of treated vessels per patient, mean (SD) 1.1 (0.3) 1.1 (0.3) .84 1.1 (0.3) 1.1 (0.3) .87
No. of stents per patient, mean (SD) 1.5 (0.8) 1.4 (0.7) .11 1.4 (0.7) 1.4 (0.7) .58
>2 vessels stented 0 49 (0.43) .41 0 49 (0.4) >.99
Reference vessel diameter, mean (SD), mmd 2.9 (0.5) 3.0 (0.5) <.001 3.1 (0.6) 3.0 (0.5) .09
Modified ACC lesion class B2 or C1 168 (50.8) 5128 (47.1) .20 97 (45.8) 5199 (47.3) .68
Vein bypass graft stented 22 (6.3) 300 (2.7) <.001 8 (3.7) 314 (2.81) .40
Thrombus-containing lesion 50 (15.3) 1482 (14.2) .57 19 (9.6) 1513 (14.3) .06
Stent type
Drug-eluting 301 (86.5) 9960 (85.5)
<.001
192 (89.3) 9769 (85.4)
.16
Sirolimus-eluting 28 (8.1) 1090 (9.7) 28 (13.0) 1090 (9.5)
Zotarolimus-eluting 27 (7.8) 1237 (11.0) 25 (11.6) 1239 (10.8)
Paclitaxel-eluting 114 (32.8) 2552 (22.6) 45 (20.9) 2621 (22.9)
Everolimus-eluting 122 (35.1) 4581 (40.5) 87 (40.5) 4616 (40.4)
>1 type 10 (2.9) 200 (1.8) 7 (3.3) 203 (1.8)
Bare metal 47 (13.5) 1640 (14.5) 23 (10.7) 1664 (14.6)
Minimum stent diameter, mm
<3 193 (55.5) 4848 (42.9)
<.001
95 (44.2) 4946 (43.3)
.78
≥3 155 (44.5) 6452 (57.1) 120 (55.8) 6487 (56.7)
(continued)
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the model. The ischemic model had moderate discrimination
(c statistic, 0.70 [95% CI, 0.68-0.73]) and was well calibrated
(goodness-of-fit P = .81).
Increasing age was a significant independent predictor of
bleeding, but not of ischemic events (Table 2). No tested
interactions between covariates and randomized treatment
for bleeding were retained in the model. The bleeding
model showed similar discrimination to the ischemia model
(c statistic, 0.68 [95% CI, 0.65-0.72]) and was well calibrated
(goodness-of-fit P = .34). After bootstrap internal validation,
optimism-corrected c statistics for both the ischemia (0.68
[95% CI, 0.65-0.70]) and bleeding models (0.66 [95% CI,
0.62-0.70]) were similar.
Clinical Prediction Score
A simplified risk score was generated to predict the differ-
encebetween theanticipated reduction in ischemiceventsand
theanticipated increase inbleedingeventswithcontinued thi-
enopyridine (ie, the benefit-risk difference) (Development of
a Predictive Score in the eAppendix in the Supplement). The
score, ranging from−2 to 10, assignedpoints as follows: forpa-
tients younger than 65 years, 0 points; for age 65 to younger
than75years,−1; forpatients75yearsorolder,−2; forveingraft
stent, 2; for current cigarette smoker orwithin past year, 1; for
diabetes mellitus, 1; for myocardial infarction at presenta-
tion, 1; for stent diameter less than 3mm, 1; for history of CHF
or left ventricular ejection fraction lower than30%,2; forprior
Table 2. Myocardial Infarction or Stent Thrombosis PredictionModel andModerate or Severe Bleeding
PredictionModel
Predictors of Eventsa
Predictors of Myocardial Infarction
or Stent Thrombosisb
Predictors of Moderate or Severe
Bleedingc
HR (95% CI) P Value HR (95% CI) P Value
Continued thienopyridine vs placebo 0.52 (0.42-0.65) <.001 1.66 (1.26-2.19) <.001
Myocardial infarction at presentation 1.65 (1.31-2.07) <.001
Prior PCI or prior myocardial infarction 1.79 (1.43-2.23) <.001
History of CHF or LVEF <30% 1.88 (1.35-2.62) <.001
Vein graft stent 1.75 (1.13-2.73) .01
Stent diameter <3 mm 1.61 (1.30-1.99) <.001
Paclitaxel-eluting stent 1.57 (1.26-1.97) <.001
Cigarette smoking 1.40 (1.11-1.76) .01
Diabetes mellitus 1.38 (1.10-1.72) .01
Age, per 10 y 1.54 (1.34-1.78) <.001
Peripheral arterial disease 1.49 (1.05-2.13) .03 2.16 (1.46-3.20) <.001
Hypertension 1.37 (1.03-1.82) .03 1.45 (1.00-2.11) .05
Renal insufficiency/failure 1.55 (1.03-2.32) .04 1.66 (1.04-2.66) .03
Abbreviations: CHF, congestive heart
failure; HR, hazard ratio; LVEF, left
ventricular ejection fraction; PCI,
percutaneous coronary intervention.
a Predictors of events from 12
through 30months after coronary
stenting.
b The ischemia model had a c -statistic
of 0.70 within the DAPT Study
randomized population, and
goodness-of-fit P = .81.
c The bleedingmodel had a c statistic
of 0.68 within the DAPT Study
randomized population, and a
goodness-of-fit P = .34. Moderate
or severe bleeding was defined by
Global Utilization of Streptokinase
and Tissue Plasminogen Activator
for Occluded Arteries criteria. Blank
table cells indicate no significant
association.
Table 1. Baseline Characteristics of PatientsWith vsWithout Ischemic or Bleeding Events From 12 to 30Months in the Derivation Cohort (N = 11 648)a
(continued)
Measure
Myocardial Infarction or Stent Thrombosis Events, No. (%) Moderate or Severe Bleeding Events, No. (%)b
Event
(n = 348 Patients)
No Event
(n = 11 300 Patients) P Value
Event
(n = 215 Patients)
No Event
(n = 11 433 Patients) P Value
Total stent length, mean (SD), mm 28.1 (16.8) 27.0 (16.4) .21 26.1 (15.0) 27.1 (16.5) .39
Thienopyridine at randomization
Prasugrel 138 (39.7) 3548 (31.4)
.002
63 (29.3) 3623 (31.7)
.51
Clopidogrel 210 (60.3) 7752 (68.6) 152 (70.7) 7810 (68.3)
Aspirin at randomization, mg
>100 127 (41.2) 4424 (43.7)
.41
78 (40.8) 4473 (43.7)
.46
≤100 181 (58.8) 5698 (56.3) 113 (59.2) 5766 (56.3)
Statin use at randomization 300 (86.2) 10 098 (89.4) .06 185 (86.1) 10 213 (89.4) .12
Randomization group
Placebo 225 (64.7) 5561 (49.2)
<.001
80 (37.2) 5706 (49.9)
<.001
Continued thienopyridine 123 (35.3) 5739 (50.8) 135 (62.8) 5727 (50.1)
Abbreviations: ACC, American College of Cardiology; BMI, bodymass index
(calculated as weight in kilograms divided by height in meters squared); BMS,
bare metal stent; CABG, coronary bypass artery graft; DES, drug-eluting stent;
LVEF, left ventricular ejection fraction; NSTEMI, non-ST-segment elevation
myocardial infarction; PCI, percutaneous coronary intervention; STEMI,
ST-segment elevationmyocardial infarction; TIA, transient ischemic attack.
a Zero to 2.3% of patients hadmissing values, except for the following variables,
for which up to 11.5% of the patients hadmissing values: LVEF <30%,modified
ACC lesion class B2 or C1, thrombus-containing lesion, and aspirin at
randomization.
bAs defined by Global Utilization of Streptokinase and Tissue Plasminogen
Activator for Occluded Arteries criteria.
c Race was self-reported.
dReference vessel diameter indicates the diameter of the unaffected vessel
immediately adjacent to coronary lesion.
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PCI or prior myocardial infarction, 1; and for paclitaxel-
elutingstent, 1 (Figure2).Amongthederivationcohort,ahigher
score quartile was associatedwith higher rates ofmyocardial
infarction or stent thrombosis (interactionP < .001),whereas
lower scorequartileswereassociatedwithhigher ratesofmod-
erate or severe bleeding (interaction P = .006). In addition,
higher scorequartileswereassociatedwith largerobservedrisk
reductions in myocardial infarction or stent thrombosis with
randomization to continued thienopyridine (P = .001), and
lower score quartiles were associated with greater observed
risk increases in bleeding (P = .04, Table 3).
When separated into groups (high score group [score, ≥2]
vs lowscoregroup[score,<2]), amongpatients in thehighscore
group (n = 5917), randomization to continued thienopyri-
dine was associated with larger reductions in myocardial in-
farction or stent thrombosis (2.7% for continued thienopyri-
dine vs 5.7% for placebo; risk difference [RD], −3.0% [95%CI,
−4.1%to−2.0%],P < .001)comparedwiththose inthe lowscore
group (n = 5731; 1.7% for continued thienopyridinevs2.3% for
placebo; RD, −0.7% [95% CI, −1.4% to 0.09%], P = .07; inter-
action P < .001). Conversely, randomization to continued
thienopyridinewasassociatedwith smaller increases inbleed-
ing among the high score group (1.8% for continued thieno-
pyridinevs 1.4%forplacebo;RD,0.4%[95%CI,−0.3%to1.0%],
P = .26) comparedwith the low score group (3.0% for contin-
ued thienopyridinevs 1.4%forplacebo;RD, 1.5%[95%CI,0.8%
to 2.3%], P < .001; interaction P = .02) (Figure 3; eTable 3 in
the Supplement).
The risk reduction in major adverse cardiovascular and
cerebrovascular events (defined as the composite of death,
myocardial infarction, and stroke) with continued thienopy-
ridine was significantly greater among the high score group
(4.9% for continued thienopyridine vs 7.6% for placebo; RD,
−2.7% [95% CI, −4.0% to −1.5%]; P < .001) vs the low score
group (3.7% for continued thienopyridine vs 3.8% for pla-
cebo; RD, −0.2% [95% CI, −1.2% to 0.86%]; P = .73; interac-
tion P = .001). The all-cause mortality rate was 2.1% for con-
tinued thienopyridine vs 2.1% for placebo for the high score
group (RD, 0.01% [95% CI, −0.73% to 0.76%]; P = .99) com-
paredwith 1.7% for continued thienopyridine vs0.9% for pla-
cebo for the low score group (RD, 0.73% [95% CI, 0.13% to
1.33%], P = .02; interaction P = .14 [nonsignificant]) .
Outcomes in Patients TreatedWith EES
After restricting the population to those treated with EES
(n = 4703), the rates of myocardial infarction or stent throm-
bosiswere 2.9% for continued thienopyridine vs 4.7% for pla-
cebo (RD,−1.89%[95%CI,−3.70%to−0.08%],P = .04)among
the high score group (n = 1869) and were 1.7% for continued
thienopyridinevs2.2%forplacebo(RD,−0.50%[95%CI,−1.55%
to0.56%],P = .33; interactionP = .18 [non-significant]) among
the low score group (n = 2834). The corresponding rates of
bleeding were 1.8% for continued thienopyridine vs 1.2% for
placebo (RD,0.52% [95%CI, −0.63% to 1.67%],P = .38) for the
highscoregroupand3.0%forcontinuedthienopyridinevs1.4%
for placebo in the low score group (RD, 1.67% [95% CI, 0.55%
to 2.78%], P = .003; interaction P = .15 [nonsignificant]).
(Figure 4, eTable 4 in the Supplement). All-cause mortality
occurred in2.5%for continued thienopyridinevs 1.8%forpla-
cebo (P = .31) among the high score group, and 1.9% for con-
tinued thienopyridine vs 0.7% for placebo (P = .01, interac-
tion P = .54 [nonsignificant]) among the low score group.
External Validation
Among 8136 patients who did not have a myocardial infarc-
tion, stent thrombosis, ormoderate/severebleedingwithin the
first 12 months after PCI in the PROTECT trial (validation co-
hort), themodels used to derive the predictive score (exclud-
ing thevariable reflecting randomization to continued thieno-
pyridinevsplacebo) showedmodestly reduceddiscrimination
(c statistic: ischemicmodel,0.64 [95%CI,0.58 to0.70]; bleed-
ingmodel,0.64[95%CI,0.55 to0.73]).These resultswereover-
all similar within the ZES and SES populations of the valida-
tion cohort (c statistic: ischemicmodel, 0.62 [95% CI, 0.52 to
0.72] in the ZES group and 0.64 [95% CI, 0.57 to 0.72] in the
SES group; bleeding model, 0.63 [95% CI, 0.51 to 0.76] in the
ZES group and 0.65 [95% CI, 0.53 to 0.76]in the SES group).
Because the PROTECT trial enrolled a lower-risk population
than the DAPT Study, both ischemic and bleeding event rates
were overestimated. After recalibration to the baseline event
Figure 2. Elements of Clinical Prediction Score and Distribution of Score Among Randomized DAPT Study
Patients (Derivation Cohort, 11 648 Patients)
30
25
35
20
15
10
5
0
Pa
tie
nt
s,
 %
Clinical Prediction Score
–2 –1 0 1 2 3 4 5 6 87 9 10
Variable Points
Clinical Prediction Score
Age, y
–2≥75
–165-<75
0<65
1Cigarette smoking
1Diabetes mellitus
1MI at presentation
1Prior PCI or prior MI
1Paclitaxel-eluting stent
1Stent diameter <3 mm
2CHF or LVEF <30%
2Vein graft stent
Total score range: –2 to 10
CHF indicates congestive heart
failure; LVEF, left ventricular ejection
fraction; MI, myocardial infarction;
PCI, percutaneous coronary
intervention. Variables reflect
characteristics at the time of the
index procedure. Cigarette smoking
was defined as smoking within 1 year
prior to index procedure.
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Table 3. Observed Outcomes by Treatment Group From 12 Through 30Months After Index Procedure Stratified by Prediction Score Quartile
for the Derivation Cohort
Event
No. of Patients No. of Events (%)
Risk Difference,
% (95% CI)
Interaction
P Valuea
Continued
Thienopyridine Placebo
All Patients
(n = 11 648)
Continued Thienopyridine
(n = 5862)
Placebo
(n = 5786)
Myocardial Infarction
Score
−2 to 0 1373 1356 40 (1.5) 15 (1.2) 25 (1.9) −0.73 (−1.68 to 0.21) .001
1 1501 1501 71 (2.4) 31 (2.1) 40 (2.7) −0.59 (−1.72 to 0.55)
2 1525 1486 82 (2.8) 23 (1.6) 59 (4.1) −2.56 (−3.80 to −1.33)
≥3 1463 1443 151 (5.4) 52 (3.7) 99 (7.2) −3.48 (−5.20 to −1.76)
Stent Thrombosis
Score
−2 to 0 1373 1356 3 (0.1) 1 (0.1) 2 (0.2) −0.07 (−0.33 to 0.19) <.001
1 1501 1501 11 (0.4) 5 (0.3) 6 (0.4) −0.06 (−0.51 to 0.39)
2 1525 1486 29 (1.0) 5 (0.3) 24 (1.7) −1.34 (−2.08 to −0.59)
≥3 1463 1443 54 (1.9) 12 (0.9) 42 (3.0) −2.18 (−3.23 to −1.12)
Myocardial Infarction or Stent Thrombosis
Score
−2 to 0 1373 1356 40 (1.5) 15 (1.2) 25 (1.9) −0.73 (−1.68 to 0.21) .001
1 1501 1501 71 (2.4) 31 (2.1) 40 (2.7) −0.59 (−1.72 to 0.55)
2 1525 1486 85 (2.9) 24 (1.6) 61 (4.3) −2.63 (−3.88 to −1.38)
≥3 1463 1443 152 (5.4) 53 (3.8) 99 (7.2) −3.41 (−5.13 to −1.68)
Major Adverse Cardiovascular and Cerebrovascular Eventsb
Score
−2 to 0 1373 1356 99 (3.7) 52 (3.9) 47 (3.5) 0.40 (−1.06 to 1.86) .02
1 1501 1501 110 (3.8) 50 (3.4) 60 (4.1) −0.65 (−2.04 to 0.75)
2 1525 1486 137 (4.7) 51 (3.4) 86 (6.0) −2.54 (−4.10 to −0.98)
≥3 1463 1443 221 (7.9) 91 (6.4) 130 (9.3) −2.95 (−4.97 to −0.92)
Death
Score
−2 to 0 1373 1356 43 (1.6) 28 (2.1) 15 (1.1) 0.99 (0.02 to 1.96) .33
1 1501 1501 29 (1.0) 18 (1.2) 11 (0.7) 0.49 (−0.24 to 1.22)
2 1525 1486 48 (1.6) 25 (1.7) 23 (1.6) 0.09 (−0.85 to 1.02)
≥3 1463 1443 70 (2.5) 35 (2.5) 35 (2.5) −0.06 (−1.24 to 1.11)
Moderate or Severe Bleedc
Score
−2 to 0 1373 1356 72 (2.7) 49 (3.7) 23 (1.7) 1.97 (0.71 to 3.23) .04
1 1501 1501 51 (1.8) 34 (2.3) 17 (1.2) 1.17 (0.20 to 2.14)
2 1525 1486 45 (1.5) 28 (1.9) 17 (1.2) 0.69 (−0.22 to 1.60)
≥3 1463 1443 47 (1.7) 24 (1.7) 23 (1.7) 0.03 (−0.95 to 1.01)
Moderate Bleedc
Score
−2 to 0 1373 1356 45 (1.7) 28 (2.1) 17 (1.3) 0.83 (−0.17 to 1.84) .33
1 1501 1501 37 (1.3) 26 (1.8) 11 (0.8) 1.03 (0.21 to 1.86)
2 1525 1486 26 (0.9) 18 (1.2) 8 (0.6) 0.66 (−0.04 to 1.35)
≥3 1463 1443 35 (1.3) 19 (1.3) 16 (1.2) 0.18 (−0.66 to 1.03)
Severe Bleedc
Score
−2 to 0 1373 1356 28 (1.1) 21 (1.6) 7 (0.5) 1.07 (0.27 to 1.86) .08
1 1501 1501 14 (0.5) 8 (0.6) 6 (0.4) 0.14 (−0.37 to 0.65)
2 1525 1486 19 (0.7) 10 (0.7) 9 (0.6) 0.04 (−0.56 to 0.63)
≥3 1463 1443 12 (0.4) 5 (0.4) 7 (0.5) −0.15 (−0.66 to 0.35)
a P value for interaction assesses whether the absolute risk reduction observed
between randomized treatment groups differs across quartiles of the clinical
prediction score, as assessed by theQ statistic for heterogeneity.
bMajor adverse cardiovascular and cerebrovascular events were defined by the
composite of death, myocardial infarction, or stroke.
c As defined by the Global Utilization of Streptokinase and Tissue Plasminogen
Activator for Occluded Arteries criteria.
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Figure 3. Observed Rates of Outcomes From 12 Through 30Months After Percutaneous Coronary Intervention Among Randomized Patients
by Clinical Prediction Score Group in the Derivation Cohort
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Figure 4. Observed Rates of Outcomes From 12 Through 30Months After Percutaneous Coronary Intervention Among Patients TreatedWith
Everolimus-Eluting Stents Only by Clinical Prediction Score Group in the Derivation Cohort
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rates observed in the PROTECT trial, themodels were well fit
(P = .81 for the ischemiamodel,P = .91 for thebleedingmodel)
(eAppendix in the Supplement).
Within the validation cohort, the rate of myocardial in-
farction or stent thrombosis from 12 through 30months after
PCIwasgreater among thehigh-scorepatients (n = 2848) com-
pared with the low-score patients (n = 5288; 1.5% high-score
patients vs 0.7% low-score patients; hazard ratio [HR], 2.01
[95% CI, 1.29 to 3.13], P = .002). Rates of moderate or severe
bleedingwerenot significantly different by score (0.4% in the
high-scorepatientsvs0.5% in the low-scorepatients;HR,0.69
[95% CI, 0.33 to 1.42], P = .31).
Discussion
This study developed a clinical prediction score based on is-
chemic and bleeding risk factors to help identify patientswith
greater expected benefit vs greater expected harm from con-
tinuationofdualantiplatelet therapy fromamongpatientswho
had completed 1 year of dual antiplatelet therapy after coro-
narystenttreatmentwithoutamajor ischemicorbleedingevent.
For patients randomized in the DAPT Study (derivation co-
hort) with clinical predictive scores of 2 or higher (high score
group; 50.8%), continued thienopyridinewas associatedwith
an absolute risk reduction in myocardial infarction or stent
thrombosis thatwas8.2 timesgreater than theabsolute risk in-
crease inmoderate or severe bleeding. Conversely, among pa-
tients with scores lower than 2 (low score group; 49.2%), ran-
domizationtocontinuedthienopyridinewasassociatedwithan
absolute increase in bleeding that was 2.4 times the absolute
reduction inmyocardial infarctionor stent thrombosis.Within
thePROTECTtrial (validationcohort), thehighscoregroupwas
observed tohave significantly greater ischemic risk andnosig-
nificantdifference inbleedingrisk,comparedwiththe lowscore
group. Despite prior evidence suggesting that ischemic and
bleeding risk are strongly correlated,3,18 these results suggest
that itmay be possible to identify individual patientswith dis-
cordant ischemic risks and bleeding risks.
Numerousrandomizedtrialsevaluatingdurationofdualan-
tiplatelet therapy after coronary stenting have demonstrated a
trade-offbetweenreductions in ischemiaandincreases inbleed-
ing associated with longer durations of treatment.19-23 Al-
though clinical trial results are expected to be applied to the
population represented by enrollment criteria, in the setting of
discordant risksandbenefitsof treatment, tailoring therapies to
individual patient profiles to maximize benefits andminimize
harms affords an opportunity to further optimize outcomes.
Anumberof limitations shouldbe considered in interpret-
ing these findings. The results of this study should be inter-
preted with the understanding that patients enrolled in clini-
cal trials may not represent those cared for in routine practice
on the basis of the inclusion and exclusion criteria of the trial,
as well as other unmeasured differences between study par-
ticipants and nonparticipants. Patients taking oral anticoagu-
lants were not enrolled in the DAPT Study, and they make up
4% to 7% of all PCI patients.24-26 Patients who interrupted
therapy formore than 14 days or sustained amajor bleeding or
ischemic event in the first year after PCIwere alsonot random-
ized in the DAPT Study, and represented 22.7%of enrolled pa-
tients. Similarly, in a recent large registry of patients undergo-
ing coronary stenting, discontinuation of antiplatelet therapy
for more than 14 days occurred in 11.5% of patients; cessation
due to a clinical event or nonadherence in 9.7%; and major
bleeding in 1.4%; whereas myocardial infarction occurred in
2.2%andtarget-vessel revascularizationin5.1%—altogetherrep-
resenting approximately 30% of all PCI patients.26 Although
there remains a sizable proportion of patients undergoing PCI
whodonothaveevents thatwouldhavedisqualifiedthemfrom
randomization in the DAPT Study, the patients used to derive
the clinical prediction score make up a group of patients that
may not be representative of those seen in clinical practice.
Variables in the predictive score included patient and pro-
cedural characteristics that have demonstrated an association
with either ischemic or bleeding events after PCI in prior stud-
ies. For instance, prior PCI, presentation with myocardial in-
farction, current smoking, anddiabeteshaveeachbeenpredic-
tive of stent thrombosis occurring within the first year after
PCI.27 Similarly, advanced age, renal disease andhistory of pe-
ripheral arterial disease have correlated with both in-hospital
and 30-day bleeding after PCI.28,29 In this study, peripheral ar-
terial disease, renal insufficiency, and hypertension were pre-
dictiveofboth ischemicandbleedingevents.Becausethese fac-
torsdidnothelp identifydiscordantbleedingand ischemic risk,
they were not included in the predictive score.
On the other hand, certain variables uniquely predicted
eitherbleeding riskor anti-ischemicbenefit: advancedagewas
predictive of increased bleeding only, whereas presentation
withmyocardial infarction, history ofCHF, andprior PCIwere
predictiveofmyocardial infarctionor stent thrombosisbutnot
bleeding.Deathsnotprecededbymyocardial infarctionorstent
thrombosiswere not considered in the creation of the predic-
tionmodel because suchdeathsmaynot bedirectlymodified
bydual antiplatelet therapy.Thismayexplainwhyagewasnot
a significant predictor of the composite ischemia end point.
Themedianpredictivescorewas2,andpatientswithascore
of 2 or higher (the high score group) had a clinicallymeaning-
ful reduction in ischemicevents (numberneededtotreat toben-
efit [NNTB], 34)with a smaller effect onbleeding eventswhen
randomized to continued thienopyridine (number needed to
treat toharm[NNTH],272),whereas thosewithscores less than
2 (the lowscore group)hada larger increase inbleedingevents
(NNTH,64) anda smaller reduction in ischemicevents (NNTB,
153). Nonetheless, scores ranging from −2 to 10 likely define a
continuousgradient of risk andbenefit. Themodelused tode-
rive thepoint values for variables requiredanassumption that
bleeding and ischemic eventswere of equalweight. However,
examinationof the results stratifiedbyscorequartile allowsas-
sessment of different score cutoffs with varied weighting of
bleedingand ischemicevents, aswell as examinationof theas-
sociation of the score with other relevant end points, includ-
ing bleeding events not classified as moderate or severe. The
ischemic and bleeding events as defined in this analysis may
not have an equivalent effect on patient outcomes, including
mortality, and the results may have been different had other
ischemic and bleeding end points been chosen.
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Although the statistical test for interaction did not show
adifference in the effect of continuationof long-termdual an-
tiplatelet therapy onmortality in high vs low score groups, it
is of interest that the numerical difference in all-cause mor-
talitywas concentratedamongpatients in the lowscoregroup.
After analyzing the results of 12 randomized trials enrolling
56 799 patients, the US Food and Drug Administration re-
cently concluded that therewas no evidence of an increase in
either cancer or mortality with extended thienopyridine
treatment.30Whether different subgroups of patients may in
facthavegreatermortalitywithcontinuationof long-termdual
antiplatelet therapy has been suggested31 and may be a topic
of future inquiry.
Paclitaxel-eluting stentswere found tobe associatedwith
higher risk of myocardial infarction or stent thrombosis. Al-
though these results are consistent with those of other
studies,32 stent type was not randomized in the DAPT Study.
As these stents are rarely used, theuse of this predictive score
going forward is unlikely to utilize this variable. In addition,
among the stents used in theDAPTStudy, onlyEES arewidely
used today. Among the EES subgroup (n = 4703), tests for in-
teraction comparing treatment effect amonghighvs lowscore
groupswerenotsignificant.However, interactiontesting isgen-
erally underpowered in clinical trials and more underpow-
ered when performed within a subset of patients. Approxi-
mately half of the risk reduction for myocardial infarction
attributed to continued thienopyridine therapy in the DAPT
Studywas not attributable to stent thrombosis,1 and bleeding
risk shouldnotbe influencedbystent type.Therefore, theabil-
ity of the prediction rule to stratify patient risks for myocar-
dial infarction unrelated to stent thrombosis and for bleeding
should not vary by stent type.
The incorporation of more variables into the individual
bleeding and ischemia models may have improved discrimi-
nation, at the expense of parsimony. In addition, the estima-
tion of risks based on the use of the separate ischemic and
bleeding model coefficients rather than use of the simplified
score could improve theability topredict suchevents, andpro-
vide theopportunity forclinicians to identifypatientswithcon-
cordantlyhigh ischemicandbleeding risks, inaddition to those
withdiscordant risks (Estimationof IschemicandBleedingRisk
in the eAppendix in the Supplement).
Although the development of the score was prespecified,
the analysis should be considered exploratory. Thus, use of
this prediction score should be cautious until further valida-
tion is performed, and optimal clinical and procedural care to
reduce overall bleeding and ischemic risks should be prac-
ticed independent of a patient’s score. Preexisting anemia,
prior bleeding, and granular measures of atherosclerosis
extent and severity were not available and may in part
explain themodest discrimination of the ischemia and bleed-
ing prediction. In addition, patients receiving ticagrelor or
other antiplatelet combinations could have a different risk-
benefit relationship. The score is relevant to patients with
characteristics similar to those enrolled in the DAPT Study,
and its generalizability to other patient populations not stud-
ied in the trial may be limited. Although BMS-treated
patients were included, the score is not applicable to patients
for whom a BMS is selected due to high risk of bleeding or
nonadherence. The end points considered in developing the
score, although well defined and adjudicated, are heteroge-
neous in severity. Although the PROTECT trial served as an
external population for validation, it was not a randomized
trial of dual antiplatelet therapy duration, and the observed
duration of therapy was likely influenced by patient risk fac-
tors. Therefore, these data could only be used to evaluate
whether the score stratified patient ischemic or bleeding risk,
and not actual benefit or harm with long-term dual antiplate-
let therapy. These results would ideally be replicated in a
similarly designed, large randomized trial of different dura-
tions of dual antiplatelet therapy among PCI patients. Use of
the clinical score has not been demonstrated to improve
patient outcomes.
Conclusions
Among patients not sustaining major bleeding or ischemic
events 1 year after PCI, a prediction rule assessing late ische-
mic andbleeding risks to informdual antiplatelet therapydu-
ration showed modest accuracy in derivation and validation
cohorts. This rule requires further prospective evaluation to
assess potential effects on patient care, as well as validation
in other cohorts.
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